Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Tu.B.2280,Tu.D.2780,Tu.Di2928,
Tu.D.354, We.A.5 I, We.A.51I2,
We.A.5 I13, We.C.35 I17, We.C.3522
female, SEE women
Mo.C. 1601, Mo.C.450, Pub.C.l1131,
Pub.D. I1302, Tu.D.2785
fetal HIV infection
Tu.A.2009,Tu.C.2572
fever
Mo.B. 1366, Mo.B. 1367, Mo.C.324,
Pub.B. I 054, Th.B.4300, Tu.B.2 179,
We.B.3220
flow cytometry
Mo.A. 1058, Mo.A. 1071, Mo.A.5 I13,
Mo.B. 1350, Pub.A. 1008, Pub.B. 1085,
ThA. I160, Th.A. I16 I, Th.A. I163, Th.A. I164,
Th.A.400 1, Th.A.4002, Th.A.4006,
Th.A.4009, Th.A.40 I19, Th.A.4085,
Tu.A.2004, Tu.A.2027, Tu.A. 2108,
Tu.B.2 3 13,Tu. B.2330, Tu. B.2 344,
We.A. 3043, We.A.3053, We.A. 3055,
We.A.3060, We.A.3068, We.A,3069,
We.A.3082, We.A.3092, We.A. 3097,
We.B.3 302, We.B.3349
fluconazole
Mo.B. I I I, Mo.B.I112, Mo.B.I116,
Mo.B, 196, Mo.B. 1228, Mo.B. 1229,
Tu.B. I 86,Tu.B.2 I 97,Tu.B.2 I 98,Tu.B.4 I,
WeB.32 I19, We.B.3223, We.B.3305
flucytosine
Th.A.4062
fluorescent antibody technique
MoC. 15 37, Th.A.4009, Th.A.4088,
Tu.B.22 I18
foscarnet
Mo.A. 1054, MoB. 113, MoB. I1190,
Mo.B. 1218, Mo.B. 1220, No.8.430,
Th.A. I 55, Th. B. 306, Th. B.4 195, Th. B.4 199,
Th.B.420 I,Th.B.4332,Tu.B.2 I185,
Tu.B.2 I187, We.8.32 I16, We.B.32 I18
functional status
Mo.D. 1877, Pub.B. I1040, To.B.2 144,
Tu.B.2 I 47, Tp. B.2 339, Tu.B.2341I,
We.A.305 I, We.B.3263
functional status
We.B.3342
fungal infections, SEE specific infections
Mo~B. 1227, Mo.B. 1230, No.8. I1232,
Mo.B. 131 8, Mo.C. I 407, Th. B.4204,
3 h.B.4207, Th.B.4208, VLB.42 I10,
foa. B.21I7 5, Tu. B.2 199.1 u. B.4 I I,
We.B.3219, We.B.3222, We.B.3224,
We.8 3225, We.B.3321, We.B.3343,
We.C.3408
gag gene
Mo.A. I1082, Th.A. 1012, Tu.A.2058
gag proteins
Mo.A. 1032, Mo.A. 154, Mo.A. 156.
Th.A.382,Th.A.383, We.A. I152, We.A, 154
ganciclovir
Mo.A. 1043, Mo.B. 11I3, Mo.B. 12 18,
No.8.1221, Mo.B. 1223, Mo.B.127 1,
Mo.B.430,Th.A.394,Th.B.30 I, 10.B.302,
Th.B.303, Th.B. 305, Tbh.B.306, 16.8.4 1 93,
Th.B.4 I 95,Th.B.4 I 99,Th.B.4332,
Tu.B8.21I83, Tu.B.2 I184, Tu.B.21I85,
Th.B.2 I 86,Tu.B.2 I 87,1.8.2 19 I,

gay community
Mo.C. I586, Mo.D. I698, Mo.D. I792,
Mo.D. I181I2, Mo.D.494, Mo.D.58 1,
Pub. D. 1464, Pub. D.1I466, Th. C.45 70,
Th.C.4650, Tu.C.2 I14, Tu.D1.2832,
Tu.D.2858,Tu.D.2925, u.D.2.947,
Tu.D.2955,Tu.D.484,i1U.D.603,
We.C.3390, We.C.442, We.D.3780,
We.D1.3795, We.D.3903
gay men
Mo.C. 14 I 1, Ma.C. 1438, Ma.C. 1467,
Mo.C. 1561, Mo.C. 1573, Mo.C. 1670,
Mo.D. 1715, Mo.D. 1793, Mo.D. 1847,
Mo.D. 1862, Pub.C.l 1119, Pub.C.I1120,
Pub.D. 1330, Pub.D. I1372, Pub.D. 1372,
Pub.D. 1464, Pub.D. I1466, Th.8.4 169,
Th.B.4240, Th.C.203, Th.C.4368,
Th.D.360, Th.[D. 365, Th.D.S 109.
Th.D.5 181,Tu.B.2335, To.B.2340, To.B.54 I,
Tu.C.2392, Tu.C.2 395, Tu.C.2 399,
Tu.C.240 I, Tu.C.2405, Tu.C.2408,
Tu.C.24 I 8,Tu.C.242 I,Tu.C.2520,
Tu.C.433, Tu.D.2834, Tu.L.2858,
Tu. D.29 56, Tu.D. 362, Tu. D. 364, Tu.D. 603,
We.A.3044, We.A.3094, We.C.2 12,
WeC.2 I S, We.C.34 I18, We.C.3422,
We.C.3454, We.C.3487, We.C.3488,
We.C.560, We.C.563, We.D.3660
gay men, drugs
Pub.C. I1257,7Th.C.4670, Th.D.5094,
Tu.C.2402, Tu.C.2403, Tu.C.24 I12,
Tu.C.24 I13, Tu.C.24 I14, Tu.C.24 17,
We.C.3490, We.C.349 I, We.C.560
gay men, ethnic groups
We.C.3497
gay men, incidence
Ma.C. 1429, Pub.C. I 11I5, Tu.C.2389,
Tu.C.2409, To.C.24 I15, Tu.C.573,
We.C.226
gay men, media
Mo.D. I181I7, Mo.D.495, Pub.D. 1392,
Pub.D. I 464,Tu.D.2885, Tu.D.475
gay men, neurology
Mo.D. I1828
gay men, neuropsychology
We.B.331 I
gay men, other
Mo.8. I1248, Th.C.4650, Tli.[.5 195,
Tua.D.2889, We.C.348 I
gay men, politics
Tu.[.2959, Tu.D.480, We.C.3390,
We.C.35 76
gay men, prevalence
Mo.B.1I235, Mo.C. I4 1 6, Ma.C.1I429,
Mo.C. 1433, Ma.C. 1 634, Mo.D.490,
Pub.C. 11I00, Tu.B.2 3 36, Tu.C.2389,
Tu.C.24 I0, Tu.C.24 I I,Tu.C.24 16,
Tu.C.242 I,Tu.C.2422
gay men, prevention
Mo.D. 171I 1, MoD. 1783, Mo.D. 1793,
Mo.D. 1817, Mo.[3.493, No.11.495,
Mo.D.581, Pub.A.102 3, Pub.C.I1163,
Pub.C. 11I64, Pub.D. 1 443, Pob.D. I146 1,
Pub.D. 1464, Pob.D. I1466, Y.C.320,
Th.C.4647, 1h.C.4650,Th.C.4662,
Th. D. 50 1 0, Th.D.5 I 94, Tu. C.2 399,
Tu.C.2406, Tu.C.24 I 3,Tu.C.242 1,

We.B.338 1, We.C.339 I, We.C.3400,
We.C.3457, We.C.34 70

gay men, psychosocial
Mo.C.1586 MoD 1725, Mo.D,1734,
Mo.D. 1777, Mo.D I 786,Mo.D. 1875,
Pub.D. I 376,Tb o 46-'7 1h.D.256,
Th.D.5 159 T1,Di6' 16 1.5170,
Th.D.51I rh D5 19 ',IF D.5195,
Tu.D.283 a uI a 32,We 6.3309,
We. B.3312,Wa.B?'; We.C.3489,
We.C.3493, We. U.372,vVe.D.3748,
We.D.3801 We 73836
gay men, SEE eduction
Pob.C. 11I63, We.C.3495
gay men, SEE sexual behaviour
MoD. I1699, MoD. 1710, M o. D.493,
Mo.D.495, Pub.C, I 1I16, Pob.D. 1502,
Tu.C.2393, We.C.347 I, We.D.380 I
gay men, seroconversion
Mo.C.32.4,T.C.2418, To.C.434,
To.D.292 1, We. C. 562
gay men, subgroups
Mo.D. I171I5, Mo.D.1I803. Pob.C. I257,
Pub.D. I 463,Th.[2.364,To.C.2396,
Tu.C.2687,Tu.D.27 I I,To.D.362,
We.C.3486, We.C.3492,
We.C.3498,We.C.562.We.D.3628,
Mo.C.324, We.11.372
gender
No.8.1344, No.8. 1389, MoC. 1419,
MoC. 1,467, MoC. I1542
gender
MoC.1579, MoD. 1700, Mo.D. 1712,
MoD. 1719, MoD. 1723, Mo.D. 1732,
Pob.C.I1128, Pub.D.131 1, Pob.D. 13 17,
Pob.D. 1325, Pob..1336, Pob.D. 1338,
Th.B. I192, T.B.290,T LC.204, Th.C.4420,
T6.C.4472, Th.C.4506, T6.C.4507,
Th.C.4559, Th.C.477,Th.C.4833,
Th. D.23 3, Th.D.5005, Tu.B.2 134,
To.B.2336, T.C.2445, Ta.[.24 1,
To.D.2705,To.D.2723,Io.D.2728,
To.D.274 I, T.D.2775, To.D.2786,
To.D.2863,Toa.D.2864, Th.D.2907,
To.D.60 I, We.C.3422, We.C.3443,
WeD.365, We.D.3663
gene amplification
MoC.1447, Mo.C. 1,448, Pob.A. 1004,
Pob.A.1017/,1-h.A.4034 1 6.A.4036,
buA. 150, lo.A.2018. lii A 2058,ITu.C.22 3
gene probes
To.A.265
gene products
Mo.A. 1090, Mo.A. I 092,1Th.A.38 I
gene products, endonuclease
Mo.A. 1019
gene products, env
Mo.A. I SOMoC. I532,Pob.A. 10 17,Pob.A.
I 02 I,Tu.A.20 I 3,laA.207 I,lau.A.37 I buA.
5 I10,1 o.A.5 I 2,11..228 I,We.A. 390,We.B.
3351
gene products, gag
Mo.A. I 027,Mo.A. I 50,Mo.A. I 54,Mo.C. I1S
32,16.A.383,Th.A.37 I,We.A.3052
gene products, nef
No.A. I O34,To A.203 3,We.A.265,We.A.3
052
gene products, other
No.A. 1034

gene therapy
M o.A. 104 2, M o.A. 1043 M o. A. 1044,
Mo.A. 1045, Mo.A. 1046, Mo.A. 1047,
Mo.A. 1049. Mo.A. ISO, No.8. I1I27,
Pub.A. I1022, 1h.A.380, Tu.A.2 I100,
Tu.A.27 I, Tu.B.228 I, We.A.270,
We.A.27 1, We.A.2 72, We.A.273,
We.A.274, We.A.3078, We.A.390,
We.B.293, We.B.3 I80, We.B.3 181,
WeB.3 I183
general population
Mo.D.1780, Mo.D. 1827, Mo.D,1832,
Mo.D. I842,Th.C.4370,l6h.C.45 18,
Th.C.452 I,Th.C.4604,lh.C.47 I12,
Th.C.47 16, Th. D. 365, Th.D.4870,
Tu.D.272 I,To.D.472
genetic diversity
Mo.A. 1018, Mo.A.285, Ma.C. 1447,
Ho.C. 144, Ma.C. 1536, Mo.C. I1667,
Pub.A. I 0 I1B, Pob.A. I102 I, Pob.A. 1024,
Th.A.4035, Th. B.4255, To.A. I100, Tu.A. 101,
TuA. I103, To.A. I 04, Tu.A.2055, Tu.A.2060,
ToA.2065, To.A.2068, Ta.A.2069,
To.A.2075, Tu.A.2.077, To.A.2078,
Tu.A.2080, T.A.2084, Tu.A.2085,
To.A.2096, Tu.A.2 65, To.A.372, Ta.A.375,
Tu.A.375,To.A.5 I I,To.B.2 I 98,To.B.3 12,
We.A. 141,We.A.282, We.A.404,
We.B.31I68, We.C.340, We.C.34 I,
We.C.342, We.C.345, Mo.A.164
genetic mutations
Pub.A. 102 I, Pub. B. I1045, Th.A. 141,
Th.A.408I1,1 6.8.4343,16.8.4349,
Tu.A.206 I., T.A.265, b.C.2695
genetic recombination
Pob.A. 102 I,bouA. I100, Tu.A.2077,
Tu.A.5 10, Tu.A.5 I I
genetic variability
Mo.A. 1036, Mo.A.273, Mo.A.285,
Mo.A.5 10. Pob.A. 10 17, Pub.A. I101 8,
16.B.4324, Tu.A. I103, Tu.A. I105, Tu.A.2053,
T.A.2054,bo.A,2058,Tu.A..206 I,
T.A.2064,bo.A.2065,To.A.2067,
Tu.A.2073, bo.A.2074,bo.A.2075,
bu.A.2078, bo.A.208 I, 11.A.2085,
lo.A.2087, bo.A.2095, To.A.374, Tbo.A.5 I12,
lu.A.S I13,bo.B.2239,bo.B.2245,Tu.C.220,
bu.C 221, b.C.222, Tu.C.2697,
We.B.3283, We.C.2 14, We.C.343,
We.C.345
genital ulcer disease (GUD)
Ma.C. 1413. Ma.C. I1625, Po6.B. 1048,
Pub.C. 1287,16.8. 1 10,116.8. 111,116..115,
T6.B.4172, Io.B.2230,lo.C.2687,
We.B.3 I185, We.C.224
genital warts
We.C.3402
genitourinary system
MNo.8B.1302.16.8.1 I2,T.8.4190,
16.8.4343. W e.A.303 3, We.C.3402
genome, new genes
We.A. 161
genomic diversity
Mo.A. 1005, No.8.31I I, Ma.C. 1443,
Ma.C. 1447. Ma.C.1448. Ma.C. 1455,
Pub.A. 101 1, Pob.A. 101 9,lTh.A.395,
bu.A. I100,lou.A. 101,Tu.A. I155, Tu.A.2052,

Pub.D. 1327, Pub.D2. 1359, Pub.D. 1368,
Pub..382, Pub.D. I1384, Pub.D. I1400,

0
U
C
0
C
0
U
C
C
C
485